IOL Chemicals post Q1 FY26 consolidated profit at Rs. 33.93 Cr
IOLCP has reported total income of Rs. 559.06 crores during the period ended June 30, 2025
IOLCP has reported total income of Rs. 559.06 crores during the period ended June 30, 2025
The partnership aims to co-develop technologies set to revolutionize manufacturing of plasmid DNA (pDNA), a critical raw material for advanced medicines
These filings come after FDA issued its latest warning to patients and healthcare professionals about the serious dangers of compounded GLP-1 drugs
Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint
Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research
The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter
Cenexi reports an EBITDA breakeven for the quarter
Athena is also exploring the use of this technology for expanded carrier screening
Vasograin Plus represents a major advancement in the treatment of migraine
Subscribe To Our Newsletter & Stay Updated